Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature

Heart Lung. 2012 Sep-Oct;41(5):512-7. doi: 10.1016/j.hrtlng.2011.09.005. Epub 2011 Nov 3.

Abstract

We describe a 76-year-old former smoker with a diagnosis of combined pulmonary fibrosis and emphysema associated with pulmonary hypertension and rapidly progressive right heart failure, in whom combined treatment with sitaxsentan and sildenafil resulted in sustained improvement of his clinical condition and exercise performance, without any relevant adverse events. Combined pulmonary fibrosis and emphysema comprises a recently identified syndrome, probably related to tobacco use, and characterized by the coexistence of upper-lobe emphysema and fibrotic changes of the lower lobes, preserved lung volumes, significant hypoxemia, and a high prevalence of pulmonary hypertension, resulting in severe dyspnea. To date, no prospective series, to the best of our knowledge, has reported on the effects of pulmonary vasodilator therapy in such patients.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Follow-Up Studies
  • Humans
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Lung Diseases, Interstitial / complications*
  • Lung Diseases, Interstitial / diagnosis
  • Male
  • Piperazines / therapeutic use*
  • Pulmonary Circulation / drug effects
  • Purines / therapeutic use
  • Radiography, Thoracic
  • Respiratory Function Tests
  • Sildenafil Citrate
  • Smoking / adverse effects*
  • Sulfones / therapeutic use*
  • Vasodilator Agents / therapeutic use*

Substances

  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate